$36.73
Legend Biotech


Performance
Dividends
1W
1M
YTD
1Y
3Y
25/36
Growth
Score
12/36
Dividend
Score
Valuation
PE Ratio
-10.37
PS Ratio
4.23
RSI
-
0
PEG Ratio
-0.04
3
PRG Ratio
0.06
PDG Ratio
0
Growth
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
3
Rule
of 40
130.69%
2
Gross Margin
61.77%
3
Current Ratio
4.71
Return on Assets
-19.28%
Return on Equity
-30.95%
Return on inv. Capital
-16.22%
Institutional Holder
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 627.24M
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 -158.13M
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 392.66M
2018
2019
2020
2021
2022
2023
2024
6
Events

LEGN
Legend Biotech
in 262 days
before market open
Earnings per Share is expected with - and revenue with - .

LEGN
Legend Biotech
in 199 days
before market open
Earnings per Share is expected with - and revenue with - .

LEGN
Legend Biotech
in 81 days
before market open
Earnings per Share is expected with -$0.12 +64.71% and revenue with 279.16M$ +74.25% YoY.
About
Sector/Industry
Healthcare
Biotechnology
IPO Date
05.06.2020
MaketCap
3.38B
Country
US
CEO
Ying Huang
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Updated 12.08.2025